AstraZeneca, United Kingdom
Thorsten Gutjahr is a distinguished scientist and leader in Precision Medicine, Biomarkers and Companion Diagnostics. He develops precision medicine solutions with a focus on Oncology. Since 2014, Thorsten has held the position of Global Head of Companion Diagnostics at AstraZeneca, within the Precision Medicine and Genomics function. He leads an Oncology CDx team that has delivered 19 new Diagnostic tests, including diagnostics for Olaparib, Osimertinib, Durvalumab and Gefitinib. Thorsten plays a leadership role in the development of AstraZeneca’s Precision Medicine strategy, with Diagnostic development of multigene panels and novel ctDNA approaches a key focus.
Before joining AstraZeneca, Thorsten was at Roche for >12 years, both in the Pharmaceuticals and the Diagnostics Division. He led the personalised healthcare teams for Trastuzumab and Erlotinib, and delivered >30 biomarkers for Diagnostics. Thorsten studied at the Universities of Stuttgart-Hohenheim & Tubingen (Germany), and the University of Sussex (UK). He gained his PhD in molecular biology at the University of Stuttgart, and completed a post-doc at the Hematology/Oncology School of Medicine, University of California in San Diego.
On 20/21 November 2018, the DLR Project Management Agency took part in the ICPerMed Conference 2018 'Personalised Medicine in Action' as one of the organisers. In its function as editor of the website of the 'ICPerMed International Consortium', the DLR Project Management Agency agreed to upload the presentations held during this event to this website thus making them available for download in pdf format subject to the express consent of the speakers concerned. DLR, as the uploading entity, has not monitored the contents of these presentations in any way. In case of incorrect contents, copyright infringements or other violations of the law, please contact the ICPerMed Secretariat (e-mail: ICPerMed@dlr.de). Any offending material will be removed immediately.